IL153497A0 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the compositionInfo
- Publication number
- IL153497A0 IL153497A0 IL15349701A IL15349701A IL153497A0 IL 153497 A0 IL153497 A0 IL 153497A0 IL 15349701 A IL15349701 A IL 15349701A IL 15349701 A IL15349701 A IL 15349701A IL 153497 A0 IL153497 A0 IL 153497A0
- Authority
- IL
- Israel
- Prior art keywords
- composition
- dosage forms
- therapeutic agents
- controlled release
- forms including
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Manufacturing & Machinery (AREA)
- Psychology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21383200P | 2000-06-23 | 2000-06-23 | |
US21711000P | 2000-07-10 | 2000-07-10 | |
US22321200P | 2000-08-04 | 2000-08-04 | |
PCT/US2001/020134 WO2002000213A1 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153497A0 true IL153497A0 (en) | 2003-07-06 |
Family
ID=27395915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15349701A IL153497A0 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1305021A4 (xx) |
JP (1) | JP2004501190A (xx) |
KR (1) | KR20030013460A (xx) |
AU (2) | AU6872201A (xx) |
CA (1) | CA2412490A1 (xx) |
CZ (1) | CZ2003199A3 (xx) |
EA (1) | EA200300046A1 (xx) |
HU (1) | HUP0301465A3 (xx) |
IL (1) | IL153497A0 (xx) |
MX (1) | MXPA02012793A (xx) |
WO (1) | WO2002000213A1 (xx) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
IL160363A0 (en) * | 2001-08-16 | 2004-07-25 | Oregon State | Expandable gastric retention device |
BE1015608A6 (fr) | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
ES2278314T3 (es) * | 2003-04-17 | 2007-08-01 | Jallal Messadek | Formulaciones orales para la liberacion controlada de la betaina. |
AU2004285436C1 (en) * | 2003-10-20 | 2009-07-16 | Teva Pharmaceutical Industries Ltd. | Composition and dosage form for sustained effect of levodopa |
JP2005132803A (ja) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | 胃内滞留固形剤 |
TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
EP2242489A1 (en) | 2005-02-15 | 2010-10-27 | Jallal Messadek | Combination therapeutic compositions and method of use |
BRPI0610249A2 (pt) | 2005-04-27 | 2010-06-08 | Jallal Messadek | associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina |
NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
KR20090057349A (ko) * | 2006-05-31 | 2009-06-05 | 솔베이 파머슈티컬스 게엠베하 | 레보도파/칼비도파의 24시간의 장기간 장내투여 |
EP1872775A1 (en) | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
AR062659A1 (es) * | 2006-09-08 | 2008-11-26 | Drug Tech Corp | Composicion de liberacion sostenida de levodopa y metodo para su uso |
BRPI0622039B1 (pt) * | 2006-09-26 | 2020-11-10 | Plensat, Llc | dispositivos gástricos ingeríveis de qualidade alimentícia |
EP2105133A1 (en) | 2007-01-15 | 2009-09-30 | Kissei Pharmaceutical Co., Ltd. | Intragastric floating-type levodopa sustained-release preparation |
KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
DE102007026037A1 (de) * | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentives System mit Alginat-Körper |
JP2010534721A (ja) * | 2007-07-27 | 2010-11-11 | ディポメド,インコーポレイティド | パルス型胃滞留性製剤 |
KR101950635B1 (ko) | 2008-06-30 | 2019-05-20 | 토카겐 인크. | 5-플루오르시토신 제제 및 이의 용도 |
JP2012500221A (ja) * | 2008-08-15 | 2012-01-05 | ディポメド,インコーポレイティド | Cns障害の処理及び予防のための胃保持性医薬組成物 |
CN102238946B (zh) * | 2008-11-07 | 2014-11-26 | 株式会社三养生物制药 | 用于哌醋甲酯的控制释放的药物组合物 |
WO2012093974A1 (en) * | 2011-01-06 | 2012-07-12 | Mahmut Bilgic | Improved bisphosphonate formulations |
CN103385871B (zh) * | 2012-05-07 | 2017-06-23 | 新疆医科大学 | 复方左旋多巴微囊漂浮片 |
EP2858604B1 (en) | 2012-06-07 | 2024-02-21 | Epitomee Medical Ltd | Expanded device |
WO2014174388A1 (en) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of methylphenidate or salts thereof |
JP6204141B2 (ja) * | 2013-04-22 | 2017-09-27 | テイカ製薬株式会社 | 口腔内速崩壊性固形製剤用組成物 |
US10994013B2 (en) | 2013-04-24 | 2021-05-04 | Temple University—Of the Commonwealth System of Higher Education | Solid dosage form containing arabinogalactan |
WO2015054302A1 (en) | 2013-10-07 | 2015-04-16 | Impax Laboratories, Inc. | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
CN105899198A (zh) * | 2013-12-05 | 2016-08-24 | 图利普医疗有限公司 | 用于药物活性试剂的原位释放的滞留装置和系统 |
KR20170134409A (ko) * | 2015-02-27 | 2017-12-06 | 싱귤레이트 테라퓨틱스 엘엘씨 | 트리펄스 방출 자극제 제형 |
JP6823539B2 (ja) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | 胃内滞留性錠剤 |
US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
DK3648747T3 (da) | 2017-06-16 | 2022-11-28 | Amneal Complex Products Res Llc | Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler |
EP3824881B1 (en) | 2018-06-18 | 2022-02-16 | Amneal Complex Products Research LLC | Extended release compositions comprising pyridostigmine |
US10744083B2 (en) | 2018-06-27 | 2020-08-18 | Kashiv Biosciences, Llc | Self-regulating osmotic gastroretentive drug delivery systems |
JP7044649B2 (ja) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | 胃内浮遊錠剤 |
CA3139217A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
US11571402B2 (en) * | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
EP1003483A1 (en) * | 1997-07-23 | 2000-05-31 | Perio Products Ltd | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
-
2001
- 2001-06-22 CA CA002412490A patent/CA2412490A1/en not_active Abandoned
- 2001-06-22 JP JP2002504995A patent/JP2004501190A/ja active Pending
- 2001-06-22 EA EA200300046A patent/EA200300046A1/ru unknown
- 2001-06-22 IL IL15349701A patent/IL153497A0/xx unknown
- 2001-06-22 HU HU0301465A patent/HUP0301465A3/hu unknown
- 2001-06-22 CZ CZ2003199A patent/CZ2003199A3/cs unknown
- 2001-06-22 AU AU6872201A patent/AU6872201A/xx active Pending
- 2001-06-22 KR KR1020027017538A patent/KR20030013460A/ko not_active Application Discontinuation
- 2001-06-22 MX MXPA02012793A patent/MXPA02012793A/es not_active Application Discontinuation
- 2001-06-22 WO PCT/US2001/020134 patent/WO2002000213A1/en active IP Right Grant
- 2001-06-22 EP EP01946709A patent/EP1305021A4/en not_active Withdrawn
- 2001-06-22 AU AU2001268722A patent/AU2001268722B8/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU6872201A (en) | 2002-01-08 |
EA200300046A1 (ru) | 2003-10-30 |
MXPA02012793A (es) | 2004-07-30 |
KR20030013460A (ko) | 2003-02-14 |
CZ2003199A3 (cs) | 2003-12-17 |
HUP0301465A3 (en) | 2006-07-28 |
CA2412490A1 (en) | 2002-01-03 |
AU2001268722B2 (en) | 2005-08-11 |
HUP0301465A2 (hu) | 2004-05-28 |
AU2001268722B8 (en) | 2005-09-29 |
EP1305021A1 (en) | 2003-05-02 |
WO2002000213A1 (en) | 2002-01-03 |
JP2004501190A (ja) | 2004-01-15 |
EP1305021A4 (en) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6872201A (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
IL154521A0 (en) | Contraception process and administration form for the same | |
HUP0301325A3 (en) | Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition | |
MXPA03003895A (es) | Formulaciones de hidrocodona de liberacion controlada. | |
HUP0301242A3 (en) | Controlled release drug dosage form | |
AU2001253479A1 (en) | Targeted therapeutic agent release devices and methods of making and using the same | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
AU2001280597A1 (en) | Compositions for sustained release of analgesic agents, and methods of making and using the same | |
MXPA02004770A (es) | Composiciones terapeuticas y metodos para su uso. | |
IL153708A0 (en) | Benzimidazole derivatives, preparation and therapeutic use thereof | |
IL151890A0 (en) | Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
EP1257255A4 (en) | THERAPEUTIC PRODUCT, ITS USE AND MANUFACTURE | |
GB0002386D0 (en) | Therapeutic composition | |
FI20000780A (fi) | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi | |
MXPA03004303A (es) | DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR. | |
EP1501352A4 (en) | METHOD AND COMPOSITIONS FOR PROTRACTED ACTIVE SUBSTANCE | |
IL151891A0 (en) | Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
IL151765A0 (en) | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | |
HUP0102159A3 (en) | Pharmaceutical composition for the treatment of rumen acidosis | |
HUP0204417A3 (en) | Oral ciprofloxacin-composition of controlled release | |
GB0030067D0 (en) | Therapeutic agent | |
EP1357898A4 (en) | ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE | |
HK1046848A1 (en) | Specific therapeutic composition for treating aids | |
HK1055954A1 (en) | Crystalline therapeutic agent. | |
IL135993A0 (en) | Pharmaceutical composition for the treatment of fibrosis |